Related Experiment Videos
In vitro assessment for neurotoxicity of antitumor agents before local administration into central nervous system
S Moriuchi1, K Shimizu, Y Miyao
1Department of Neurosurgery, Center for Adult Diseases, Osaka, Japan.
Abstract:
In vitro assays for neurotoxicity with the aid of cultured mouse fetal neurons and glial cells were applied to investigate neurotoxicity of recombinant murine interferon-beta (rMuIFN-beta). These data were compared with those for MTX, ADR, and ACNU. The range of concentrations of the drugs used in these experiments spanned their clinically achievable concentrations in patient serum (IFN-beta: 1 x 10(4) IU/ml, MTX: 100 micrograms/ml, ADR: 20 micrograms/ml, ACNU: 20 micrograms/ml). rMuIFN- beta damaged both neurons and glial cells at concentrations of more than 1 x 10(5) IU/ml but did not damage them at 1 x 10(4) IU/ml or less. Microtubule-associated protein 1A (MAP1A) staining was decreased in rMuIFN-beta-treated (more than 1 x 10(5) IU/ml) neutrons. In conclusion, since IFN-beta may have some neurotoxic effects at concentrations higher than 1 x 10(5) IU/ml, it should be administered carefully, as should other antitumor agents, into the tumor cavity in the CNS following surgery.
Insights
Recombinant murine interferon-beta (rMuIFN-beta) shows neurotoxic effects on mouse neurons and glial cells at high concentrations. Careful administration of interferon-beta is recommended for central nervous system (CNS) tumors.
Area of Science:
- Neuroscience
- Toxicology
- Pharmacology
Background:
- Interferon-beta (IFN-beta) is an antitumor agent with potential central nervous system (CNS) applications.
- Neurotoxicity is a significant concern for CNS-acting drugs.
- Understanding the specific neurotoxic profile of IFN-beta is crucial for safe clinical use.
Purpose of the Study:
- To investigate the in vitro neurotoxicity of recombinant murine interferon-beta (rMuIFN-beta).
- To compare the neurotoxic effects of rMuIFN-beta with other antitumor agents (MTX, ADR, ACNU).
- To determine the concentration-dependent neurotoxic effects of rMuIFN-beta on neurons and glial cells.
Main Methods:
- Utilized in vitro assays with cultured mouse fetal neurons and glial cells.
- Exposed cells to various concentrations of rMuIFN-beta, MTX, ADR, and ACNU, reflecting clinically achievable serum levels.
- Assessed cell viability and performed Microtubule-associated protein 1A (MAP1A) staining.
Main Results:
- rMuIFN-beta demonstrated neurotoxic effects on both neurons and glial cells at concentrations exceeding 1 x 10(5) IU/ml.
- No significant damage was observed at concentrations of 1 x 10(4) IU/ml or lower.
- MAP1A staining was reduced in neurons treated with rMuIFN-beta at concentrations above 1 x 10(5) IU/ml.
Conclusions:
- IFN-beta exhibits neurotoxic potential at concentrations higher than 1 x 10(5) IU/ml.
- Cautious administration of IFN-beta is advised, particularly when delivered into the CNS tumor cavity post-surgery.
- These findings highlight the importance of dose-dependent neurotoxicity assessment for therapeutic agents used in CNS treatments.